Published in Am J Clin Oncol on December 01, 2015
Self-reported conflicts of interest of authors, trial sponsorship, and the interpretation of editorials and related phase III trials in oncology. J Clin Oncol (2013) 2.68
Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol (2013) 2.27
Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst (2007) 2.14
Risk Factors for Mortality and Outcomes in Pediatric Acute Lung Injury/Acute Respiratory Distress Syndrome. Pediatr Crit Care Med (2015) 1.39
Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol (2005) 1.27
Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest (2002) 1.24
Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol (2007) 1.20
Adverse drug reactions and drug interactions as causes of hospital admission in oncology. J Pain Symptom Manage (2011) 1.14
Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res (2003) 1.12
Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clin Colorectal Cancer (2011) 0.87
Survival is not a good outcome for randomized trials with effective subsequent therapies. J Clin Oncol (2011) 0.87
Use of unnecessary medications by patients with advanced cancer: cross-sectional survey. Support Care Cancer (2010) 0.85
Poor evidence to standardize adjuvant treatment for patients with biliary tract cancer. J Clin Oncol (2012) 0.84
CALGB 9633: an underpowered trial with a methodologically questionable conclusion. J Clin Oncol (2009) 0.84
Massive orbital metastasis of hepatocellular carcinoma. Clinics (Sao Paulo) (2006) 0.82
A systematic review on drug interactions in oncology. Cancer Invest (2006) 0.82
Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors. Rare Tumors (2013) 0.80
Increasing output and low publication rate of Brazilian studies presented at the American Society of Clinical Oncology Annual Meetings. Clinics (Sao Paulo) (2008) 0.80
Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil. Rev Assoc Med Bras (2009) 0.79
Potential economic impact of the 21-gene expression assay on the treatment of breast cancer in Brazil. Rev Assoc Med Bras (2010) 0.77
Targeted drugs in oncology: new names, new mechanisms, new paradigm. Am J Health Syst Pharm (2003) 0.76
Progression-free survival in neuroendocrine tumors: preferred end point, but how should it be defined? J Clin Oncol (2011) 0.76
ERCC1 in advanced biliary tract cancer patients treated with chemotherapy: prognostic and predictive roles. J Gastrointest Cancer (2014) 0.76
Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer. Invest New Drugs (2004) 0.76
Antitumor effect of everolimus in a patient with type 3 gastric neuroendocrine tumor. Onkologie (2013) 0.76
Drug combinations with the potential to interact among cancer patients. Support Care Cancer (2007) 0.75
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med (2009) 0.75
Reply to R. Brierley et al. J Clin Oncol (2013) 0.75
Quality of reporting primary outcomes in phase II cancer trials. J Clin Oncol (2008) 0.75
Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials. Cancer Treat Rev (2011) 0.75